Bradley Wilcox, DO
Pulmonary Disease · Des Moines, IANPI 1760401657
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (48.2%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 89.4% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2020 at $4,833 and has fallen 98.7% since, to $62 in 2025.
Across 39 payments — averaging $184.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- Johnson & Johnson$137
- Sanofi$122
- La Jolla Pharmaceutical Company$109
- Abiomed$79
- Inari Medical, Inc.$71
- plus $247 from 8 others
What the payments were for
- Travel & lodging$2,70538%
- Food & beverage$1,02214%
- Education$3,46548%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 22 | $6,426 |
| Johnson & Johnson | 1 | $137 |
| Sanofi | 1 | $122 |
| La Jolla Pharmaceutical Company | 1 | $109 |
| Abiomed | 3 | $79 |
| Inari Medical, Inc. | 1 | $71 |
| ERBE USA Inc | 1 | $56 |
| Amgen | 2 | $48 |
| Davol Inc. | 2 | $46 |
| Galvanize Therapeutics, Inc | 1 | $38 |
| Boston Scientific | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Insmed, Inc. | 1 | $14 |
| Siemens Medical Solutions USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,843
- MONARCH$137
- DUPIXENT$122
- GIAPREZA$109
How this compares
$7,191 in reported general payments places this provider in the 75th percentile of 110 pulmonary disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $149,988 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $36,562 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $21,525 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 46 | $21,194 |
| EliquisApixaban | 23 | $15,100 |
| Advair HfaFluticasone Propion/Salmeterol | 31 | $14,529 |
| Spiriva RespimatTiotropium Bromide | 22 | $11,463 |
| Incruse ElliptaUmeclidinium Bromide | 23 | $11,058 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,860 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 46 | $4,594 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $2,742 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $2,723 |
| Advair DiskusFluticasone Propion/Salmeterol | 11 | $2,259 |
| Azithromycin | 114 | $2,060 |
| Mycophenolate Mofetil | 11 | $1,378 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSpiriva Respimat | $15 | $11,46322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 110 pulmonary disease providers in Iowa.
Other pulmonary disease in Des Moines
- Shrey VelaniDes Moines$18K
- Neil HorningDes Moines$15K
- Jason WittmerDes Moines$10K
- Blair WesterlyDes Moines$7K
- Eric AsbeDes Moines$4K
- Maxwell CosmicDes Moines$3K
- Anthony GrecoDes Moines$3K
- Lucas Silqueira Hickson CruzDes Moines$2K
- Maksym PuliaievDes Moines$2K
- Bryon JohnsonDes Moines$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.